Anti-TNF Therapies in IBD: Opinion Leader Insight into Current & Future Treatment Practices
Sociable Pharma, April 2011, Pages: 130
Since the introduction of infliximab for the treatment of Crohn's disease in 1999, anti-TNF therapies have begun to reshape the treatment landscape for inflammatory bowel disease. There are now well-established treatment strategies for biologics in both Crohn's disease and ulcerative colitis but it will be the movement of anti-TNF therapies to earlier treatment settings in both diseases that will be the dominant macro-trend in the future. Sociable Pharma conducted in-depth primary research in the US and across Europe with key opinion leaders to understand how anti-TNF therapy is currently used in the treatment of inflammatory bowel disease and how it will evolve in the future.
Report highlights:
- SWOT analysis of three leading Anti-TNF therapies, including relative immunogenicity concerns
- Includes SWOT analysis for Humira, Remicade and Cimzia
- Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
- Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as top down treatment strategies and combination therapies
- Assesses threats from novel oral inhibitors and biosimilars
- Identifies new opportunities, including adherence strategies and patient monitoring
- Detailed visual guides to the treatment of Ulcerative Colitis and Crohn's Disease
Research highlights:
SWOT analysis of 3 anti-TNF therapies
- Relative immunogenicity concerns
- Comparative availability of long-term safety & efficacy data
- New opportunities from adherence strategies and patient monitoring
- Threats from novel oral inhibitors and biosimilars
KOL opinion hotspots for UC & Crohn's disease
- Top-down treatment strategies vs. accelerated step-up
- Use as monotherapy or in combination
- Duration of treatment & loss of response
Visual guides to UC & Crohn's disease
- 4 Treatment Maps & 48 treatment settings in Crohn's disease
- 4 Treatment Maps & 38 treatment settings in Ulcerative Colitis
Key evidence
- Summarizes of key evidence by line of therapy and class
Summaries of KOL opinion hotspots
- Identifies KOL opinion hotspots by line of therapy and class
Executive Summary
Scope of analysis & methodology
SWOT analysis
– Infliximab, Remicade
– Adalimumab, Humira
– Certolizumab pegol, Cimzia
KOL opinions & analysis
– Crohn's disease
– Ulcerative colitis
Treatment Maps
- Centocor
- Merck
- Abbott
- UCB Pharma
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
